Navigation Links
INNOPHARMA Receives First FDA Approval
Date:2/2/2010

MONMOUTH JUNCTION, N.J., Feb. 2 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of the Abbreviated New Drug Application (ANDA) for ibutilide fumarate injection (the generic equivalent of Corvert® from Pfizer Inc).

As the developer of this generic injectable drug, INNOPHARMA entered into a license agreement with Bioniche Pharma USA for marketing and product distribution of the injection product. Ibutilide fumarate injection represents INNOPHARMA's first approved drug in their product pipeline.

Please refer to the Bioniche Pharma website to be directed to the complete prescribing information for this product, including the boxed warning.

About INNOPHARMA:

INNOPHARMA is a research and development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of parenteral pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.  

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com.

SOURCE INNOPHARMA LLC

RELATED LINKS
http://www.innopharmallc.com

'/>"/>

SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Mylan Receives Approval for Generic Version of GoLytely(R)
3. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
4. Notal Visions ForeseeHome(TM) AMD Monitor Receives FDA Clearance
5. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
6. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
7. KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director
8. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
10. GeneGo Receives SBIR Grant
11. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Scientists from Silicon Biosystems Menarini today ... door to genetic analysis of previously preserved tumor ... isolate with 100 percent purity. Utilizing the com­pany,s ... various stages of development, the researchers were able ... are clinically relevant, and may change the way ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
(Date:2/11/2016)... 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced ... a Controlled Equity Offering SM Sales Agreement with ... Macaluso , Chairman and CEO, stated "During our most ... currently raising money and that we have enough money ... still complete all of our current objectives and nothing ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... According to an article published February 1st ... dietary supplement, is being recalled due to the discovery that it contains dangerous adulterants. ... a single supplement on the market proven to help people safety lose excess weight, ...
(Date:2/11/2016)... ... 11, 2016 , ... Dr. Sadati’s recent feature in Allure ... with performing procedures, the magazine also highlights that Dr. Sadati has pioneered new ... the most common procedures he performs is his natural facelift. “As people age, ...
(Date:2/11/2016)... ... 11, 2016 , ... The president released a FY 2017 budget request on ... more of the cost burden to military beneficiaries. , MOAA’s president, retired Air ... budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , ...
(Date:2/11/2016)... Irving, Texas (PRWEB) , ... February 11, 2016 ... ... for plastic surgery, dermatology and women’s health, is pleased to announce the promotions ... Practice Development Partners sales team, Steve Catone to executive vice president of North ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for ... the Board of Commissioners. Individuals interested in volunteer board service are encouraged to ... clinical practice settings and across allied health to contribute to its mission and ...
Breaking Medicine News(10 mins):